

19th BTOG Annual Conference 2021

Thursday 22nd April 2021

**08:00 BTOG 2021 Virtual Conference Opens
Visit the Exhibition Hall and ePosters**

**Virtual
Conference
Foyer**

09:00 – 10:50 Session 1 Opening Session

| | | |
|--------|---|---|
| 09:00 | Welcome to BTOG 2021 | Professor Sanjay Popat BTOG Steering Committee Chair |
| 09:10 | BTOG 2021 Lifetime Achievement Award Presentation | Martin Grange |
| 09:20 | ETOP Update | Rolf Stahel |
| 09:30 | NCRI Update | Matthew Hatton |
| Chair: | Matthew Evison and Stephen Harrow | |
| 09:40 | COVID19 and cancer: what did we learn? | David Pinato |
| 10:05 | Recovery, restoration and redoubling – a call to action | David Baldwin |
| 10:30 | Q&A | |
| 10:50 | Close | |

10:50 – 12:00 Please Visit the Exhibition Hall and ePosters

11:00 – 11:45 Satellite Symposium Sponsored by Bayer

12:00 – 13:00 Session 2 Oral Abstract Presentations

| | | |
|--------|--|------------------------|
| Chair: | Matthew Callister, Karen Clayton and Adam Januszewski | |
| 12:00 | What proportion of patients staged as single station N2 with pre-operative EBUS-TBNA have multi-station N2 from intra-operative lymph node staging? | Christopher Craig |
| 12:10 | Evaluation of telephone consultations for follow up lung cancer patients at Royal Papworth Hospital, undertaken instead of face-to-face consultations during the Covid-19 pandemic | Claire Haslop |
| 12:20 | Changes in management for patients with lung cancer referred for radical radiotherapy during the first wave of the COVID 19 pandemic in the UK (COVID-RT Lung) | Kathryn Banfill |
| 12:30 | Detection of Tier 1 Variants With Circulating Tumour (ct) DNA Next Generation Sequencing (NGS) in UK Non-Small Cell Lung Cancer (NSCLC) Patients | Charlotte Milner-Watts |
| 12:40 | Q&A | |
| 13:00 | Close | |

13:00 – 14:00 Please Visit the Exhibition Hall and ePosters

13:10 – 13:55 Satellite Symposium Sponsored by MSD

14:00 – 15:00 Session 3 Parallel Speciality Sessions

Translational Oncology

Chairs: Shobit Bajjal and Tom Newsom-Davis

| | | |
|-------|---|-----------------|
| 14:00 | Antibody drug conjugates: a new era in lung cancer? | Jarushka Naidoo |
| 14:15 | Targeting KRAS: has the wait been worth it? | Colin Lindsay |
| 14:30 | Cell therapies in thoracic malignancies: hope or hype | Andrew Furness |
| 14:45 | Q&A | |
| 15:00 | Close | |

Radiotherapy

Chairs: Fiona McDonald and Clive Peedell

| | | |
|-------|--|-------------------|
| 14:00 | Introduction | |
| 14.02 | Where are we with the role of PORT post LungArt? | Cecile Le Pechoux |
| 14.22 | Q&A | |
| 14.32 | Re-irradiation of lung cancer: How do we make it safe? | Robert Rulach |
| 14.47 | Q&A | |
| 15:00 | Close | |

Respiratory Medicine & Radiology

Chairs: Neal Navani and Richard Booton

| | | |
|-------|---|----------------|
| 14:00 | What are the lessons from GIRFT? | Paul Beckett |
| 14:15 | Questions to Dr Beckett | |
| 14:20 | Solutions for thoracic imaging capacity – what can we learn from breast cancer | Caroline Rubin |
| 14:35 | Questions to Dr Rubin | |
| 14:40 | Debate - Management of malignant pleural effusion: Pleurodesis vs Indwelling pleural catheter | |
| 14:40 | Pleurodesis | Najib Rahman |
| 14:47 | Indwelling pleural catheter | Eleanor Mishra |
| 14:54 | Q&A | |
| 15:00 | Close | |

14:00 – 16:00 BTOG Advocates Meeting 2021

BTOG defines advocates as those who sit on clinical studies or trial management groups, advisory boards/groups or other related groups related to lung cancer or mesothelioma. Advocates can register [here](#)

15:00 – 16:00 Please Visit the Exhibition Hall and ePosters

15:10 – 15:55 Satellite Symposium Sponsored by MSD

16:00 – 17:00 Session 4 The Patient Experience

Chairs: Josie Roberts and Sanjay Agrawal

| | | |
|-------|---|-----------------|
| 16:00 | The patient experience | Debra Montague |
| 16:10 | How do we improve the patient experience? | Vanessa Beattie |
| 16:20 | Virtual consults: a step forward or backward? | Robert Rintoul |
| 16:40 | Q&A | |
| 17:00 | Close of Day 1 | |

19th BTOG Annual Conference 2021

Friday 23rd April 2021

Please visit the Exhibition Hall and ePosters

**Virtual
Conference
Foyer**

09:00 – 10:30 Session 5 Focusing on Cure

Chairs: John Edwards and James Spicer

| | | |
|-------|---|---------------------|
| 09:00 | Immunotherapy: moving to operable disease? | Samreen Ahmed |
| 09:20 | TKIs: moving to operable disease? | Ross Soo |
| 09:40 | Surgical considerations in a peri-operative therapy era | Rory Beattie |
| 10:00 | Mixing immunotherapy with radiotherapy | Corinne Faivre-Finn |
| 10:20 | Q&A | |
| 10:50 | Close | |

10:50 – 12:00 Please Visit the Exhibition Hall and ePosters

11:00 – 11:45 Satellite Symposium Sponsored by Takeda

12:00 – 13:00 Session 6 Translating the Science

Chairs: Keith Kerr and Adam Dangoor

| | | |
|-------|--|--------------------|
| 12:00 | WHO knows how to classify thoracic cancers? | Angeles Montero |
| 12:20 | NSCLC biomarker testing: what, how, when, where? | Alastair Greystoke |
| 12:40 | Q&A | |
| 13:00 | Close | |

13:00 – 14:00 Please Visit the Exhibition Hall and ePosters

13:10 – 13:55 Satellite Symposium Sponsored by Amgen

14:00 – 15:00 Session 7 UK Sub-group Sessions

BTOG – NCRI Advanced Disease

| | | |
|-------|--|----------------|
| 14:00 | Introduction to the portfolio | Fiona Blackall |
| | Key Challenges and Questions in... | |
| 14:05 | Radiotherapy in advanced stage disease | Kevin Franks |
| 14:13 | Immunotherapy for advanced NSCLC | Riyaz Shah |
| 14:21 | Oncogenic driven NSCLC | Samreen Ahmed |
| 14:29 | SCLC | Robin Young |
| 14:37 | Quality of life with advanced lung cancer: can it be improved? | Lynn Calman |
| 14:45 | Q&A | |
| 15:00 | Close | |

14:00 – 15:00 Session 7 UK Sub-group Sessions

BTOG – NCRI Mesothelioma

| | | |
|-------|-------------------------------|-----------------|
| 14:00 | Introduction to the portfolio | Peter Szlosarek |
| 14:10 | MIST | Dean Fennell |
| 14:20 | PREDICT-Meso Accelerator | Kevin Blyth |
| 14:30 | New Studies | Peter Szlosarek |
| 14:40 | Q&A | |
| 15:00 | Close | |

BTOG – NCRI Screening & Early Diagnosis

| | | |
|-------|--|-------------------|
| 14:00 | Introduction / Portfolio Review | Philip Crosbie |
| 14:05 | The Yorkshire Lung Screening Trial: An update | Matthew Callister |
| 14:15 | Calibration of the LLP Lung Cancer stratification model: prospective validation in the UKLS cohort of 76,000 people | John Field |
| 14:25 | Lung screening uptake from a behavioural science perspective | Samantha Quaife |
| 14:35 | Risk based targeted screening - can we do better? | Mikey Lebrecht |
| 14:45 | Q&A | |
| 15:00 | Close | |

BTOG – NCRI LocoRegional Disease (LORD)

| | | |
|-------|--|------------------|
| 14:00 | Introduction to the portfolio | Mary O'Brien |
| 14:10 | Surgical update: Novel technologies and oncological challenges | Leanne Ashrafian |
| 14:20 | Chemo/RT post ADSCAN: portfolio gaps | Matthew Hatton |
| 14:30 | adj/neo adj +/-io in stage III | Mary O'Brien |
| 14:40 | Q&A | |
| 15:00 | Close | |

BTOG – Lung Cancer Nursing UK

| | | |
|-------|---|--------------------------------|
| 14:00 | Introduction | Cathy Henshall/Jackie Fenemore |
| 14:05 | Communicating lung cancer recurrence risk following surgery: A multiple qualitative case study | Matthew Johnson |
| 14:30 | Gendered Experiences of Mesothelioma (The GEMS Study) | Stephanie Ejegi-Memeh |
| 14:55 | Research Interest Group (RIG) Update & Summary | Cathy Henshall/Jackie Fenemore |
| 15:00 | Close | |

15:00 – 16:00 Please Visit the Exhibition Hall

15:00 – 16:00 Meet the Poster Presenters

16:00 – 17:00 Session 8 Closing Session

Chairs: David Gilligan and Martin Forster

| | | |
|-------|--|-----------------|
| 16:00 | Immunotherapy in mesothelioma: when, how and why | Riyaz Shah |
| 16:15 | Roadmap to maximizing small cell survival | Fiona Blackhall |
| 16:30 | Is cardio-oncology relevant for thoracic malignancies? | Alexander Lyon |
| 16:45 | Q&A | |
| 17:00 | Close of BTOG 2021 | |

See you for BTOG 2022 - 26th to 28th January 2022 – Please Save the Dates